Zinger Key Points
- VYD2311 showed a 17-fold higher potency than pemivibart in in vitro tests, with sustained high serum concentrations at Day 65.
- Invivyd's Q4 2024 Pemgarda revenue hit $13.8 million, up 48% from Q3, with $69.3 million in year-end cash reserves.
On Monday, Invivyd Inc. IVVD shares rallied on the heels of a new data report involving a COVID-19 treatment.
The company is conducting an ongoing Phase 1/2 trial of VYD2311, a monoclonal antibody (mAb) candidate. A formal estimate of in vivo half-life is not yet available for VYD2311 given the long apparent half-life thus far.
As of Day 65, serum concentrations remain high, potentially substantially increasing the observed half-life of VYD2311 relative to pemivibart, the company’s monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID‑19.
Also Read: What’s Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
Analysis for the IM cohort (the most advanced cohort in time) is tracking generally with the PK profile of adintrevimab, a previous Invivyd mAb with an estimated in vivo half-life of 139 days.
PK analysis of VYD2311 intravenous and subcutaneous cohorts at earlier timepoints, at either similar doses subcutaneously or higher doses intravenously, are similarly and encouragingly tracking close to the estimated curves for adintrevimab thus far.
In vitro neutralization data generated continuously on VYD2311 as part of Invivyd’s industrial virology efforts demonstrate an average potency improvement for VYD2311 of approximately 17-fold compared to pemivibart.
The combined safety, pharmacokinetics (PK), and virology data for VYD2311, along with findings from Invivyd’s CANOPY Phase 3 trial and previous monoclonal antibody (mAb) studies, suggest that VYD2311 could offer strong and long-lasting protection against COVID-19.
A single dose may provide high protective antibody levels for six months to a year or longer.
The company also reported preliminary fourth quarter 2024 Pemgarda (pemivibart) net product revenue of $13.8 million. That’s 48% growth over Q3 2024 net product revenue of $9.3 million.
The company’s preliminary ending 2024 cash and cash equivalents of $69.3 million.
Price Action: Invivyd stock is up 72.8% at last check Tuesday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
